Longeveron (LGVN) Interest Expenses (2020 - 2026)

Longeveron's (LGVN) quarterly Interest Expenses came in at $770000.0 in Q1 2026, down 41.44% year-on-year from $1.3 million in Q1 2025, and down 9.73% quarter-over-quarter from $853000.0 in Q4 2025.

Longeveron (LGVN) Interest Expenses (2020 - 2026) Analysis & Trends

Longeveron's Interest Expenses history runs 7 years deep, the most recent figure standing at $770000.0 for Q1 2026.

  • On a quarterly basis, Interest Expenses fell 41.44% year-over-year to $770000.0 in Q1 2026; TTM through Mar 2026 was $770000.0, a 41.44% decrease from a year earlier, with the FY2025 full-year figure at $1.1 million, down 94.15% from the prior year.
  • Interest Expenses slipped to $770000.0 in Q1 2026 per LGVN's latest filing, from $853000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $38.0 million in Q1 2023 and bottomed at -$12000.0 in Q4 2022.
  • The 5-year median for Interest Expenses is $702000.0 (2022), against an average of $2.8 million.
  • Across the five-year window, Interest Expenses jumped 5313.11% in 2023 and tumbled 99.41% in 2024, its largest moves.
  • Year by year, Interest Expenses stood at -$12000.0 in 2022, then jumped by 358.33% to $31000.0 in 2023, then soared by 3012.9% to $965000.0 in 2024, then slipped by 11.61% to $853000.0 in 2025, then slipped by 9.73% to $770000.0 in 2026.
  • Per Business Quant, the three latest LGVN Interest Expenses figures stand at $770000.0 (Q1 2026), $853000.0 (Q4 2025), and $1.5 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Int Expense (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -42,141.15
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 100,000.00
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 32.89 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 420.30 Mn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 28.30 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - 1.17 Bn
10 Longeveron 14.87 Bn 14.86 Bn 264,000.00 770,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 770,000.00
Mar 31, 2026 770,000.00
Dec 31, 2025 853,000.00
Dec 31, 2025 853,000.00
Sep 30, 2025 1.47 Mn
Sep 30, 2025 1.47 Mn
Jun 30, 2025 1.41 Mn
Jun 30, 2025 1.41 Mn
Mar 31, 2025 1.32 Mn
Mar 31, 2025 1.32 Mn
Dec 31, 2024 965,000.00
Dec 31, 2024 965,000.00
Sep 30, 2024 224,000.00
Sep 30, 2024 224,000.00
Jun 30, 2024 47,000.00
Jun 30, 2024 47,000.00
Mar 31, 2024 224,000.00
Mar 31, 2024 224,000.00
Dec 31, 2023 31,000.00
Dec 31, 2023 31,000.00